Neuropsychiatric ramifications of severe COVID-19 and other severe acute respiratory infections
<p><strong>Importance:</strong> Individuals surviving severe COVID-19 may be at increased risk of neuropsychiatric sequelae. Robust assessment of these risks may improve clinical understanding of the post-COVID syndrome, aid clinical care during the ongoing pandemic, and inform pos...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Medical Association
2022
|
| _version_ | 1797107349908881408 |
|---|---|
| author | Clift, AK Ranger, T Patone, M Coupland, C Hatch, R Thomas, K Hippisley-Cox, J Watkinson, P |
| author_facet | Clift, AK Ranger, T Patone, M Coupland, C Hatch, R Thomas, K Hippisley-Cox, J Watkinson, P |
| author_sort | Clift, AK |
| collection | OXFORD |
| description | <p><strong>Importance:</strong> Individuals surviving severe COVID-19 may be at increased risk of neuropsychiatric sequelae. Robust assessment of these risks may improve clinical understanding of the post-COVID syndrome, aid clinical care during the ongoing pandemic, and inform post-pandemic planning.</p>
<p><strong>Objective:</strong> To quantify the risks of new-onset neuropsychiatric conditions, and new neuropsychiatric medication prescriptions following discharge from a COVID-19-related hospitalization. To compare these to risks after discharge from hospitalization for other severe acute respiratory infections (SARI) during the COVID-19 pandemic.</p>
<p><strong>Design:</strong> Cohort study from 24th January 2020 to 7th July 2021.</p>
<p><strong>Setting:</strong> QResearch primary care and linked electronic health record databases, including national SARS-CoV-2 testing, hospital episode statistics, intensive care admissions data, and mortality registers in England.</p>
<p><strong>Participants:</strong> Adults aged 18+ years.</p>
<p><strong>Exposures:</strong> COVID-19 or SARI-related hospital admission (including intensive care admission).</p>
<p><strong>Main outcomes and measures:</strong> New-onset diagnoses of neuropsychiatric conditions (anxiety, dementia, psychosis, depression, bipolar disorder) or first prescription for relevant medications (antidepressants, hypnotic/anxiolytics, antipsychotics) during 12 months follow-up from hospital discharge. Maximally-adjusted hazard ratios (HR) with 95% confidence intervals (CI) were estimated using flexible parametric survival models.</p>
<p><strong>Results:</strong> The cohort comprised 8.38 million adults (4.18 million women, 4.20 million men; mean age 49.18 years): 16,679 survived a hospital admission for SARI, and 32,525 survived a hospital admission for COVID-19. Compared to the remaining population, SARI and COVID-19 hospitalization survivors had higher risks of all subsequent neuropsychiatric diagnoses, e.g.: anxiety (HR 1.86 [95% CI: 1.56-2.21] and 2.36 [2.03-2.74], respectively); dementia (2.55 [2.17-3.00] and 2.63 [2.21-3.14]). Similar trends were observed for all medications analysed, e.g., first prescriptions of anti-depressants (HR 2.55 [95% CI: 2.24-2.90], 3.24 [2.91-3.61], respectively). There were no significant differences observed when directly comparing the COVID-19 group to the SARI group apart from a lower risk of anti-psychotic prescriptions in the former (HR 0.80, 95% CI 0.69-0.92).</p>
<p><strong>Conclusions and relevance:</strong> The neuropsychiatric sequelae of severe COVID-19 are similar to those for other severe acute respiratory infections. This may inform post-discharge support for people surviving severe respiratory acute infections.</p> |
| first_indexed | 2024-03-07T07:13:17Z |
| format | Journal article |
| id | oxford-uuid:11099339-2bd5-42f4-bf0f-c74541d4d110 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:13:17Z |
| publishDate | 2022 |
| publisher | American Medical Association |
| record_format | dspace |
| spelling | oxford-uuid:11099339-2bd5-42f4-bf0f-c74541d4d1102022-07-28T10:00:18ZNeuropsychiatric ramifications of severe COVID-19 and other severe acute respiratory infectionsJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:11099339-2bd5-42f4-bf0f-c74541d4d110EnglishSymplectic ElementsAmerican Medical Association2022Clift, AKRanger, TPatone, MCoupland, CHatch, RThomas, KHippisley-Cox, JWatkinson, P<p><strong>Importance:</strong> Individuals surviving severe COVID-19 may be at increased risk of neuropsychiatric sequelae. Robust assessment of these risks may improve clinical understanding of the post-COVID syndrome, aid clinical care during the ongoing pandemic, and inform post-pandemic planning.</p> <p><strong>Objective:</strong> To quantify the risks of new-onset neuropsychiatric conditions, and new neuropsychiatric medication prescriptions following discharge from a COVID-19-related hospitalization. To compare these to risks after discharge from hospitalization for other severe acute respiratory infections (SARI) during the COVID-19 pandemic.</p> <p><strong>Design:</strong> Cohort study from 24th January 2020 to 7th July 2021.</p> <p><strong>Setting:</strong> QResearch primary care and linked electronic health record databases, including national SARS-CoV-2 testing, hospital episode statistics, intensive care admissions data, and mortality registers in England.</p> <p><strong>Participants:</strong> Adults aged 18+ years.</p> <p><strong>Exposures:</strong> COVID-19 or SARI-related hospital admission (including intensive care admission).</p> <p><strong>Main outcomes and measures:</strong> New-onset diagnoses of neuropsychiatric conditions (anxiety, dementia, psychosis, depression, bipolar disorder) or first prescription for relevant medications (antidepressants, hypnotic/anxiolytics, antipsychotics) during 12 months follow-up from hospital discharge. Maximally-adjusted hazard ratios (HR) with 95% confidence intervals (CI) were estimated using flexible parametric survival models.</p> <p><strong>Results:</strong> The cohort comprised 8.38 million adults (4.18 million women, 4.20 million men; mean age 49.18 years): 16,679 survived a hospital admission for SARI, and 32,525 survived a hospital admission for COVID-19. Compared to the remaining population, SARI and COVID-19 hospitalization survivors had higher risks of all subsequent neuropsychiatric diagnoses, e.g.: anxiety (HR 1.86 [95% CI: 1.56-2.21] and 2.36 [2.03-2.74], respectively); dementia (2.55 [2.17-3.00] and 2.63 [2.21-3.14]). Similar trends were observed for all medications analysed, e.g., first prescriptions of anti-depressants (HR 2.55 [95% CI: 2.24-2.90], 3.24 [2.91-3.61], respectively). There were no significant differences observed when directly comparing the COVID-19 group to the SARI group apart from a lower risk of anti-psychotic prescriptions in the former (HR 0.80, 95% CI 0.69-0.92).</p> <p><strong>Conclusions and relevance:</strong> The neuropsychiatric sequelae of severe COVID-19 are similar to those for other severe acute respiratory infections. This may inform post-discharge support for people surviving severe respiratory acute infections.</p> |
| spellingShingle | Clift, AK Ranger, T Patone, M Coupland, C Hatch, R Thomas, K Hippisley-Cox, J Watkinson, P Neuropsychiatric ramifications of severe COVID-19 and other severe acute respiratory infections |
| title | Neuropsychiatric ramifications of severe COVID-19 and other severe acute respiratory infections |
| title_full | Neuropsychiatric ramifications of severe COVID-19 and other severe acute respiratory infections |
| title_fullStr | Neuropsychiatric ramifications of severe COVID-19 and other severe acute respiratory infections |
| title_full_unstemmed | Neuropsychiatric ramifications of severe COVID-19 and other severe acute respiratory infections |
| title_short | Neuropsychiatric ramifications of severe COVID-19 and other severe acute respiratory infections |
| title_sort | neuropsychiatric ramifications of severe covid 19 and other severe acute respiratory infections |
| work_keys_str_mv | AT cliftak neuropsychiatricramificationsofseverecovid19andothersevereacuterespiratoryinfections AT rangert neuropsychiatricramificationsofseverecovid19andothersevereacuterespiratoryinfections AT patonem neuropsychiatricramificationsofseverecovid19andothersevereacuterespiratoryinfections AT couplandc neuropsychiatricramificationsofseverecovid19andothersevereacuterespiratoryinfections AT hatchr neuropsychiatricramificationsofseverecovid19andothersevereacuterespiratoryinfections AT thomask neuropsychiatricramificationsofseverecovid19andothersevereacuterespiratoryinfections AT hippisleycoxj neuropsychiatricramificationsofseverecovid19andothersevereacuterespiratoryinfections AT watkinsonp neuropsychiatricramificationsofseverecovid19andothersevereacuterespiratoryinfections |